Pharma & Healthcare

JAK1 Inhibitors - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

The global market for JAK1 Inhibitors was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for JAK1 Inhibitors was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for JAK1 Inhibitors was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for JAK1 Inhibitors was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of JAK1 Inhibitors include Pfizer, Incyte, Novartis, Eli Lilly, CTI Bio, Jyseleca, Gilead, Sanofi and AbbVie, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for JAK1 Inhibitors, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of JAK1 Inhibitors by region & country, by Type, and by Application.
The JAK1 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding JAK1 Inhibitors.
Market Segmentation
By Company
Pfizer
Incyte
Novartis
Eli Lilly
CTI Bio
Jyseleca
Gilead
Sanofi
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
Segment by Type:
Ruxolitinib
Baricitinib
Upadacitinib
Others
Segment by Application
Myelofibrosis (MF)
Polycythemia Vera (PV)
Graft Versus Host Disease (GVHD)
Atopic Dermatitis (AD)
Rheumatoid Arthritis (RA)
Ulcerative Colitis (UC)
Ankylosing Spondylitis (AS)
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of JAK1 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of JAK1 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of JAK1 Inhibitors in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 JAK1 Inhibitors Product Introduction
1.2 Global JAK1 Inhibitors Market Size Forecast
1.2.1 Global JAK1 Inhibitors Sales Value (2019-2030)
1.2.2 Global JAK1 Inhibitors Sales Volume (2019-2030)
1.2.3 Global JAK1 Inhibitors Sales Price (2019-2030)
1.3 JAK1 Inhibitors Market Trends & Drivers
1.3.1 JAK1 Inhibitors Industry Trends
1.3.2 JAK1 Inhibitors Market Drivers & Opportunity
1.3.3 JAK1 Inhibitors Market Challenges
1.3.4 JAK1 Inhibitors Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global JAK1 Inhibitors Players Revenue Ranking (2023)
2.2 Global JAK1 Inhibitors Revenue by Company (2019-2024)
2.3 Global JAK1 Inhibitors Players Sales Volume Ranking (2023)
2.4 Global JAK1 Inhibitors Sales Volume by Company Players (2019-2024)
2.5 Global JAK1 Inhibitors Average Price by Company (2019-2024)
2.6 Key Manufacturers JAK1 Inhibitors Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers JAK1 Inhibitors Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of JAK1 Inhibitors
2.9 JAK1 Inhibitors Market Competitive Analysis
2.9.1 JAK1 Inhibitors Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by JAK1 Inhibitors Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in JAK1 Inhibitors as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Ruxolitinib
3.1.2 Baricitinib
3.1.3 Upadacitinib
3.1.4 Others
3.2 Global JAK1 Inhibitors Sales Value by Type
3.2.1 Global JAK1 Inhibitors Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global JAK1 Inhibitors Sales Value, by Type (2019-2030)
3.2.3 Global JAK1 Inhibitors Sales Value, by Type (%) (2019-2030)
3.3 Global JAK1 Inhibitors Sales Volume by Type
3.3.1 Global JAK1 Inhibitors Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global JAK1 Inhibitors Sales Volume, by Type (2019-2030)
3.3.3 Global JAK1 Inhibitors Sales Volume, by Type (%) (2019-2030)
3.4 Global JAK1 Inhibitors Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Myelofibrosis (MF)
4.1.2 Polycythemia Vera (PV)
4.1.3 Graft Versus Host Disease (GVHD)
4.1.4 Atopic Dermatitis (AD)
4.1.5 Rheumatoid Arthritis (RA)
4.1.6 Ulcerative Colitis (UC)
4.1.7 Ankylosing Spondylitis (AS)
4.2 Global JAK1 Inhibitors Sales Value by Application
4.2.1 Global JAK1 Inhibitors Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global JAK1 Inhibitors Sales Value, by Application (2019-2030)
4.2.3 Global JAK1 Inhibitors Sales Value, by Application (%) (2019-2030)
4.3 Global JAK1 Inhibitors Sales Volume by Application
4.3.1 Global JAK1 Inhibitors Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global JAK1 Inhibitors Sales Volume, by Application (2019-2030)
4.3.3 Global JAK1 Inhibitors Sales Volume, by Application (%) (2019-2030)
4.4 Global JAK1 Inhibitors Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global JAK1 Inhibitors Sales Value by Region
5.1.1 Global JAK1 Inhibitors Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global JAK1 Inhibitors Sales Value by Region (2019-2024)
5.1.3 Global JAK1 Inhibitors Sales Value by Region (2025-2030)
5.1.4 Global JAK1 Inhibitors Sales Value by Region (%), (2019-2030)
5.2 Global JAK1 Inhibitors Sales Volume by Region
5.2.1 Global JAK1 Inhibitors Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global JAK1 Inhibitors Sales Volume by Region (2019-2024)
5.2.3 Global JAK1 Inhibitors Sales Volume by Region (2025-2030)
5.2.4 Global JAK1 Inhibitors Sales Volume by Region (%), (2019-2030)
5.3 Global JAK1 Inhibitors Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America JAK1 Inhibitors Sales Value, 2019-2030
5.4.2 North America JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe JAK1 Inhibitors Sales Value, 2019-2030
5.5.2 Europe JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific JAK1 Inhibitors Sales Value, 2019-2030
5.6.2 Asia Pacific JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America JAK1 Inhibitors Sales Value, 2019-2030
5.7.2 South America JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa JAK1 Inhibitors Sales Value, 2019-2030
5.8.2 Middle East & Africa JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions JAK1 Inhibitors Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions JAK1 Inhibitors Sales Value
6.2.1 Key Countries/Regions JAK1 Inhibitors Sales Value, 2019-2030
6.2.2 Key Countries/Regions JAK1 Inhibitors Sales Volume, 2019-2030
6.3 United States
6.3.1 United States JAK1 Inhibitors Sales Value, 2019-2030
6.3.2 United States JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
6.3.3 United States JAK1 Inhibitors Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe JAK1 Inhibitors Sales Value, 2019-2030
6.4.2 Europe JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe JAK1 Inhibitors Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China JAK1 Inhibitors Sales Value, 2019-2030
6.5.2 China JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
6.5.3 China JAK1 Inhibitors Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan JAK1 Inhibitors Sales Value, 2019-2030
6.6.2 Japan JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan JAK1 Inhibitors Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea JAK1 Inhibitors Sales Value, 2019-2030
6.7.2 South Korea JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea JAK1 Inhibitors Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia JAK1 Inhibitors Sales Value, 2019-2030
6.8.2 Southeast Asia JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia JAK1 Inhibitors Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India JAK1 Inhibitors Sales Value, 2019-2030
6.9.2 India JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
6.9.3 India JAK1 Inhibitors Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer JAK1 Inhibitors Product Offerings
7.1.5 Pfizer Recent Development
7.2 Incyte
7.2.1 Incyte Company Information
7.2.2 Incyte Introduction and Business Overview
7.2.3 Incyte JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Incyte JAK1 Inhibitors Product Offerings
7.2.5 Incyte Recent Development
7.3 Novartis
7.3.1 Novartis Company Information
7.3.2 Novartis Introduction and Business Overview
7.3.3 Novartis JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Novartis JAK1 Inhibitors Product Offerings
7.3.5 Novartis Recent Development
7.4 Eli Lilly
7.4.1 Eli Lilly Company Information
7.4.2 Eli Lilly Introduction and Business Overview
7.4.3 Eli Lilly JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Eli Lilly JAK1 Inhibitors Product Offerings
7.4.5 Eli Lilly Recent Development
7.5 CTI Bio
7.5.1 CTI Bio Company Information
7.5.2 CTI Bio Introduction and Business Overview
7.5.3 CTI Bio JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.5.4 CTI Bio JAK1 Inhibitors Product Offerings
7.5.5 CTI Bio Recent Development
7.6 Jyseleca
7.6.1 Jyseleca Company Information
7.6.2 Jyseleca Introduction and Business Overview
7.6.3 Jyseleca JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Jyseleca JAK1 Inhibitors Product Offerings
7.6.5 Jyseleca Recent Development
7.7 Gilead
7.7.1 Gilead Company Information
7.7.2 Gilead Introduction and Business Overview
7.7.3 Gilead JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Gilead JAK1 Inhibitors Product Offerings
7.7.5 Gilead Recent Development
7.8 Sanofi
7.8.1 Sanofi Company Information
7.8.2 Sanofi Introduction and Business Overview
7.8.3 Sanofi JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Sanofi JAK1 Inhibitors Product Offerings
7.8.5 Sanofi Recent Development
7.9 AbbVie
7.9.1 AbbVie Company Information
7.9.2 AbbVie Introduction and Business Overview
7.9.3 AbbVie JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.9.4 AbbVie JAK1 Inhibitors Product Offerings
7.9.5 AbbVie Recent Development
7.10 Vertex
7.10.1 Vertex Company Information
7.10.2 Vertex Introduction and Business Overview
7.10.3 Vertex JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Vertex JAK1 Inhibitors Product Offerings
7.10.5 Vertex Recent Development
7.11 Teva
7.11.1 Teva Company Information
7.11.2 Teva Introduction and Business Overview
7.11.3 Teva JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Teva JAK1 Inhibitors Product Offerings
7.11.5 Teva Recent Development
7.12 Astellas Pharma
7.12.1 Astellas Pharma Company Information
7.12.2 Astellas Pharma Introduction and Business Overview
7.12.3 Astellas Pharma JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Astellas Pharma JAK1 Inhibitors Product Offerings
7.12.5 Astellas Pharma Recent Development
7.13 Celgene
7.13.1 Celgene Company Information
7.13.2 Celgene Introduction and Business Overview
7.13.3 Celgene JAK1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Celgene JAK1 Inhibitors Product Offerings
7.13.5 Celgene Recent Development
8 Industry Chain Analysis
8.1 JAK1 Inhibitors Industrial Chain
8.2 JAK1 Inhibitors Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 JAK1 Inhibitors Sales Model
8.5.2 Sales Channel
8.5.3 JAK1 Inhibitors Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. JAK1 Inhibitors Market Trends
Table 2. JAK1 Inhibitors Market Drivers & Opportunity
Table 3. JAK1 Inhibitors Market Challenges
Table 4. JAK1 Inhibitors Market Restraints
Table 5. Global JAK1 Inhibitors Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global JAK1 Inhibitors Revenue Market Share by Company (2019-2024)
Table 7. Global JAK1 Inhibitors Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global JAK1 Inhibitors Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market JAK1 Inhibitors Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers JAK1 Inhibitors Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers JAK1 Inhibitors Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of JAK1 Inhibitors
Table 13. Global JAK1 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in JAK1 Inhibitors as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global JAK1 Inhibitors Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global JAK1 Inhibitors Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global JAK1 Inhibitors Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global JAK1 Inhibitors Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global JAK1 Inhibitors Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global JAK1 Inhibitors Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global JAK1 Inhibitors Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global JAK1 Inhibitors Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global JAK1 Inhibitors Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global JAK1 Inhibitors Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global JAK1 Inhibitors Price by Type (2019-2024) & (US$/Unit)
Table 27. Global JAK1 Inhibitors Price by Type (2025-2030) & (US$/Unit)
Table 28. Global JAK1 Inhibitors Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global JAK1 Inhibitors Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global JAK1 Inhibitors Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global JAK1 Inhibitors Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global JAK1 Inhibitors Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global JAK1 Inhibitors Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global JAK1 Inhibitors Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global JAK1 Inhibitors Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global JAK1 Inhibitors Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global JAK1 Inhibitors Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global JAK1 Inhibitors Price by Application (2019-2024) & (US$/Unit)
Table 39. Global JAK1 Inhibitors Price by Application (2025-2030) & (US$/Unit)
Table 40. Global JAK1 Inhibitors Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global JAK1 Inhibitors Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global JAK1 Inhibitors Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global JAK1 Inhibitors Sales Value by Region (2019-2024) & (%)
Table 44. Global JAK1 Inhibitors Sales Value by Region (2025-2030) & (%)
Table 45. Global JAK1 Inhibitors Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global JAK1 Inhibitors Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global JAK1 Inhibitors Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global JAK1 Inhibitors Sales Volume by Region (2019-2024) & (%)
Table 49. Global JAK1 Inhibitors Sales Volume by Region (2025-2030) & (%)
Table 50. Global JAK1 Inhibitors Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global JAK1 Inhibitors Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions JAK1 Inhibitors Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions JAK1 Inhibitors Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions JAK1 Inhibitors Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions JAK1 Inhibitors Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions JAK1 Inhibitors Sales Volume, (2025-2030) & (K Units)
Table 57. Pfizer Company Information
Table 58. Pfizer Introduction and Business Overview
Table 59. Pfizer JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Pfizer JAK1 Inhibitors Product Offerings
Table 61. Pfizer Recent Development
Table 62. Incyte Company Information
Table 63. Incyte Introduction and Business Overview
Table 64. Incyte JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Incyte JAK1 Inhibitors Product Offerings
Table 66. Incyte Recent Development
Table 67. Novartis Company Information
Table 68. Novartis Introduction and Business Overview
Table 69. Novartis JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Novartis JAK1 Inhibitors Product Offerings
Table 71. Novartis Recent Development
Table 72. Eli Lilly Company Information
Table 73. Eli Lilly Introduction and Business Overview
Table 74. Eli Lilly JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Eli Lilly JAK1 Inhibitors Product Offerings
Table 76. Eli Lilly Recent Development
Table 77. CTI Bio Company Information
Table 78. CTI Bio Introduction and Business Overview
Table 79. CTI Bio JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. CTI Bio JAK1 Inhibitors Product Offerings
Table 81. CTI Bio Recent Development
Table 82. Jyseleca Company Information
Table 83. Jyseleca Introduction and Business Overview
Table 84. Jyseleca JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Jyseleca JAK1 Inhibitors Product Offerings
Table 86. Jyseleca Recent Development
Table 87. Gilead Company Information
Table 88. Gilead Introduction and Business Overview
Table 89. Gilead JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Gilead JAK1 Inhibitors Product Offerings
Table 91. Gilead Recent Development
Table 92. Sanofi Company Information
Table 93. Sanofi Introduction and Business Overview
Table 94. Sanofi JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Sanofi JAK1 Inhibitors Product Offerings
Table 96. Sanofi Recent Development
Table 97. AbbVie Company Information
Table 98. AbbVie Introduction and Business Overview
Table 99. AbbVie JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. AbbVie JAK1 Inhibitors Product Offerings
Table 101. AbbVie Recent Development
Table 102. Vertex Company Information
Table 103. Vertex Introduction and Business Overview
Table 104. Vertex JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Vertex JAK1 Inhibitors Product Offerings
Table 106. Vertex Recent Development
Table 107. Teva Company Information
Table 108. Teva Introduction and Business Overview
Table 109. Teva JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Teva JAK1 Inhibitors Product Offerings
Table 111. Teva Recent Development
Table 112. Astellas Pharma Company Information
Table 113. Astellas Pharma Introduction and Business Overview
Table 114. Astellas Pharma JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Astellas Pharma JAK1 Inhibitors Product Offerings
Table 116. Astellas Pharma Recent Development
Table 117. Celgene Company Information
Table 118. Celgene Introduction and Business Overview
Table 119. Celgene JAK1 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Celgene JAK1 Inhibitors Product Offerings
Table 121. Celgene Recent Development
Table 122. Key Raw Materials Lists
Table 123. Raw Materials Key Suppliers Lists
Table 124. JAK1 Inhibitors Downstream Customers
Table 125. JAK1 Inhibitors Distributors List
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. JAK1 Inhibitors Product Picture
Figure 2. Global JAK1 Inhibitors Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global JAK1 Inhibitors Sales Value (2019-2030) & (US$ Million)
Figure 4. Global JAK1 Inhibitors Sales Volume (2019-2030) & (K Units)
Figure 5. Global JAK1 Inhibitors Sales Price (2019-2030) & (US$/Unit)
Figure 6. JAK1 Inhibitors Report Years Considered
Figure 7. Global JAK1 Inhibitors Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global JAK1 Inhibitors Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by JAK1 Inhibitors Revenue in 2023
Figure 10. JAK1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Ruxolitinib Picture
Figure 12. Baricitinib Picture
Figure 13. Upadacitinib Picture
Figure 14. Others Picture
Figure 15. Global JAK1 Inhibitors Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global JAK1 Inhibitors Sales Value Market Share by Type, 2023 & 2030
Figure 17. Global JAK1 Inhibitors Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 18. Global JAK1 Inhibitors Sales Volume Market Share by Type, 2023 & 2030
Figure 19. Global JAK1 Inhibitors Price by Type (2019-2030) & (US$/Unit)
Figure 20. Product Picture of Myelofibrosis (MF)
Figure 21. Product Picture of Polycythemia Vera (PV)
Figure 22. Product Picture of Graft Versus Host Disease (GVHD)
Figure 23. Product Picture of Atopic Dermatitis (AD)
Figure 24. Product Picture of Rheumatoid Arthritis (RA)
Figure 25. Product Picture of Ulcerative Colitis (UC)
Figure 26. Product Picture of Ankylosing Spondylitis (AS)
Figure 27. Global JAK1 Inhibitors Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 28. Global JAK1 Inhibitors Sales Value Market Share by Application, 2023 & 2030
Figure 29. Global JAK1 Inhibitors Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 30. Global JAK1 Inhibitors Sales Volume Market Share by Application, 2023 & 2030
Figure 31. Global JAK1 Inhibitors Price by Application (2019-2030) & (US$/Unit)
Figure 32. North America JAK1 Inhibitors Sales Value (2019-2030) & (US$ Million)
Figure 33. North America JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
Figure 34. Europe JAK1 Inhibitors Sales Value (2019-2030) & (US$ Million)
Figure 35. Europe JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
Figure 36. Asia Pacific JAK1 Inhibitors Sales Value (2019-2030) & (US$ Million)
Figure 37. Asia Pacific JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
Figure 38. South America JAK1 Inhibitors Sales Value (2019-2030) & (US$ Million)
Figure 39. South America JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
Figure 40. Middle East & Africa JAK1 Inhibitors Sales Value (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa JAK1 Inhibitors Sales Value by Country (%), 2023 VS 2030
Figure 42. Key Countries/Regions JAK1 Inhibitors Sales Value (%), (2019-2030)
Figure 43. Key Countries/Regions JAK1 Inhibitors Sales Volume (%), (2019-2030)
Figure 44. United States JAK1 Inhibitors Sales Value, (2019-2030) & (US$ Million)
Figure 45. United States JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
Figure 46. United States JAK1 Inhibitors Sales Value by Application (%), 2023 VS 2030
Figure 47. Europe JAK1 Inhibitors Sales Value, (2019-2030) & (US$ Million)
Figure 48. Europe JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
Figure 49. Europe JAK1 Inhibitors Sales Value by Application (%), 2023 VS 2030
Figure 50. China JAK1 Inhibitors Sales Value, (2019-2030) & (US$ Million)
Figure 51. China JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
Figure 52. China JAK1 Inhibitors Sales Value by Application (%), 2023 VS 2030
Figure 53. Japan JAK1 Inhibitors Sales Value, (2019-2030) & (US$ Million)
Figure 54. Japan JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
Figure 55. Japan JAK1 Inhibitors Sales Value by Application (%), 2023 VS 2030
Figure 56. South Korea JAK1 Inhibitors Sales Value, (2019-2030) & (US$ Million)
Figure 57. South Korea JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
Figure 58. South Korea JAK1 Inhibitors Sales Value by Application (%), 2023 VS 2030
Figure 59. Southeast Asia JAK1 Inhibitors Sales Value, (2019-2030) & (US$ Million)
Figure 60. Southeast Asia JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
Figure 61. Southeast Asia JAK1 Inhibitors Sales Value by Application (%), 2023 VS 2030
Figure 62. India JAK1 Inhibitors Sales Value, (2019-2030) & (US$ Million)
Figure 63. India JAK1 Inhibitors Sales Value by Type (%), 2023 VS 2030
Figure 64. India JAK1 Inhibitors Sales Value by Application (%), 2023 VS 2030
Figure 65. JAK1 Inhibitors Industrial Chain
Figure 66. JAK1 Inhibitors Manufacturing Cost Structure
Figure 67. Channels of Distribution (Direct Sales, and Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies